The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Open accessAbstract
BACKGROUND: The existing estimate of the global burden of latent TB infection (LTBI) as "one-third" of the world population is nearly 20 y old. Given the importance of controlling LTBI as part of the End TB Strategy for eliminating TB by 2050, changes in demography and scientific understanding, and progress in TB control, it is important to re-assess the global burden of LTBI. METHODS AND FINDINGS: We constructed trends in annual risk in infection (ARI) for countries between 1934 and 2014 using a combination of direct estimates of ARI from LTBI surveys (131 surveys from 1950 to 2011) and indirect estimates of ARI calculated from World Health Organisation (WHO) estimates of smear positive TB prevalence from 1990 to 2014. Gaussian process regression was used to generate ARIs for country-years without data and to represent uncertainty. Estimated ARI time-series were applied to the demography in each country to calculate the number and proportions of individuals infected, recently infected (infected within 2 y), and recently infected with isoniazid (INH)-resistant strains. Resulting estimates were aggregated by WHO region. We estimated the contribution of existing infections to TB incidence in 2035 and 2050. In 2014, the global burden of LTBI was 23.0% (95% uncertainty interval [UI]: 20.4%-26.4%), amounting to approximately 1.7 billion people. WHO South-East Asia, Western-Pacific, and Africa regions had the highest prevalence and accounted for around 80% of those with LTBI. Prevalence of recent infection was 0.8% (95% UI: 0.7%-0.9%) of the global population, amounting to 55.5 (95% UI: 48.2-63.8) million individuals currently at high risk of TB disease, of which 10.9% (95% UI:10.2%-11.8%) was isoniazid-resistant. Current LTBI alone, assuming no additional infections from 2015 onwards, would be expected to generate TB incidences in the region of 16.5 per 100,000 per year in 2035 and 8.3 per 100,000 per year in 2050. Limitations included the quantity and methodological heterogeneity of direct ARI data, and limited evidence to inform on potential clearance of LTBI. CONCLUSIONS: We estimate that approximately 1.7 billion individuals were latently infected with Mycobacterium tuberculosis (M.tb) globally in 2014, just under a quarter of the global population. Investment in new tools to improve diagnosis and treatment of those with LTBI at risk of progressing to disease is urgently needed to address this latent reservoir if the 2050 target of eliminating TB is to be reached.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Fitted trends for annual risk of infection—Southeast Asia. Fitted trends of annual risk of tuberculosis infection (ARI) for countries in the WHO Southeast Asia region (log scale). Points represent ARI data (black circles from WHO tuberculosis prevalence estimates, blue triangles from tuberculin skin test [TST] surveys); error bars represent measurement precision to +/- one standard deviation. Red lines show the mean (solid) and +/- one standard deviation (dashed lines) of Gaussian process regression with a linear trend. Similar plots for the other WHO regions are provided in S1 Text (Figures C-H).](/paper-figures/2f0385ce53ea41a1b99cb028b8300a64/the-global-burden-of-latent-tuberculosis-infection-a-re-estimation-using-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An estimated 1.7 billion have tuberculosis infections that are “latent.”56”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dye, C., Scheele, S., >Dolin, P., Pathania, V. S., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,955
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Trunz, B. B., Fine, P., & Dye, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68507-3 · Cited by 1,114
Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection
Pai, M., Denkinger, C. M., Kik, S. V., Rangaka, M. X., Zwerling, A. A., Oxlade, O., Metcalfe, J. Z., Cattamanchi, A., Dowdy, D. W., Dheda, K. U. J., et al. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-13 · Cited by 881
A blood RNA signature for tuberculosis disease risk: a prospective cohort study
Zak, D. E., Penn‐Nicholson, A., Scriba, T. J., Thompson, E. G., Suliman, S., Amon, L. M., Mahomed, H., Erasmus, M., Whatney, W. E., Hussey, G. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01316-1 · Cited by 779
Latent Mycobacterium tuberculosis Infection
Getahun, H., Matteelli, A., Chaisson, R. E., & Raviglione, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1405427 · Cited by 776
Vynnycky, E., & Fine, P. (1997) · Epidemiology and Infection · doi:10.1017/s0950268897007917 · Cited by 562
Rangaka, M. X., Wilkinson, K. A., Glynn, J. R., Ling, D. I., Menzies, D., Mwansa-Kambafwile, J. R. M., Fielding, K., Wilkinson, R. J., & Pai, M. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70210-9 · Cited by 475
Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study
Dodd, P. J., Gardiner, E., Coghlan, R., & Seddon, J. A. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(14)70245-1 · Cited by 368
Self-citation
Cited by
Sorted by citations
Chakaya, J. M., Khan, M. S., Ntoumi, F., Aklillu, E., Fatima, R., Mwaba, P., Kapata, N., Mfinanga, S., Hasnain, S. E., Katoto, P. D., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.107 · Cited by 1,107
Furin, J. J., Cox, H. S., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 876
Skin microbiota–host interactions
Chen, Y. E., Fischbach, M. A., & Belkaid, Y. (2018) · Nature · doi:10.1038/nature25177 · Cited by 815
Ecology and evolution of Mycobacterium tuberculosis
Gagneux, S. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2018.8 · Cited by 618
The global prevalence of latent tuberculosis: A systematic review and meta-analysis
Cohen, A., Mathiasen, V. D., Schön, T., & Wejse, C. (2019) · European Respiratory Journal · doi:10.1183/13993003.00655-2019 · Cited by 547
Drain, P. K., Bajema, K. L., Dowdy, D. W., Dheda, K. U. J., Naidoo, K., Schumacher, S. G., Ma, S., Meermeier, E. W., Lewinsohn, D. M., & Sherman, D. R. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00021-18 · Cited by 587
Sterling, T. R., Njie, G. J., Zenner, D., Cohn, D. L., Reves, R. R., Ahmed, A. I., Menzies, D., Horsburgh, C. R., Crane, C. M., Burgos, M. V., et al. (2020) · MMWR Recommendations and Reports · doi:10.15585/mmwr.rr6901a1 · Cited by 514
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
Floyd, K., Glaziou, P., Zumla, A. I., & Raviglione, M. C. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30057-2 · Cited by 462
Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Meeren, O. V. D., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., van Brakel, E., Ayles, H., Henostroza, G., Thienemann, F., Scriba, T. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803484 · Cited by 419
Revisiting the timetable of tuberculosis
Behr, M. A., Edelstein, P. H., & Ramakrishnan, L. (2018) · BMJ · doi:10.1136/bmj.k2738 · Cited by 411
The X chromosome and sex-specific effects in infectious disease susceptibility
Schurz, H., Salie, M., Tromp, G., Hoal, E. G., Kinnear, C. J., & Möller, M. (2019) · Human Genomics · doi:10.1186/s40246-018-0185-z · Cited by 419
Global Epidemiology of Tuberculosis
Floyd, K., Raviglione, M. C., & Glaziou, P. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0038-1651492 · Cited by 409
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
Menzies, D., Adjobimey, M., Ruslami, R., Trajman, A., Bah-Sow, O. Y., Kim, H. J., Baah, J. O., Marks, G. B., Long, R., Hoeppner, V., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714283 · Cited by 385
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Reid, M. J. A., Arinaminpathy, N., Bloom, A., Bloom, B. R., Boehme, C. C., Chaisson, R. E., Chin, D. P., Churchyard, G., Cox, H. S., Diţiu, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30024-8 · Cited by 382
What We Know About Tuberculosis Transmission: An Overview
Churchyard, G., Kim, P. S., Shah, N., Rustomjee, R., Gandhi, N. R., Mathema, B., Dowdy, D. W., Kasmar, A. G., & Cárdenas, V. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix362 · Cited by 341
An overview of spirooxindole as a promising scaffold for novel drug discovery
Zhou, L., Qu, R., & Yang, G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1733526 · Cited by 324
Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection
Simmons, J. D., Stein, C. M., Seshadri, C., Campo, M., Alter, G., Fortune, S. M., Schurr, E., Wallis, R. S., Churchyard, G., Mayanja‐Kizza, H., et al. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0025-3 · Cited by 322
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 284
Latent tuberculosis infection: An overview
Kiazyk, S. A. K., & Ball, T. B. (2017) · Canada Communicable Disease Report · doi:10.14745/ccdr.v43i34a01 · Cited by 271
The Diagnosis and Treatment of Tuberculosis
Suárez, I., Fünger, S. M., Kröger, S., Rademacher, J., Fätkenheuer, G., & Rybniker, J. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0729 · Cited by 267
Global Epidemiology of TuberculosisPreprint
Glaziou, P., Sismanidis, C., Floyd, K., & Raviglione, M. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017798 · Cited by 271
Scriba, T. J., Penn‐Nicholson, A., Shankar, S., Hraha, T., Thompson, E. G., Sterling, D., Nemes, E., Darboe, F., Suliman, S., Amon, L. M., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006687 · Cited by 255
Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets — 2017
MacNeil, A., Glaziou, P., Sismanidis, C., Maloney, S. A., & Floyd, K. (2019) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6811a3 · Cited by 252
A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes
Chowdhury, R. R., Vallania, F., Yang, Q., Angel, C. J. L., Darboe, F., Penn‐Nicholson, A., Rozot, V., Nemes, E., Malherbe, S. T., Ronacher, K., et al. (2018) · Nature · doi:10.1038/s41586-018-0439-x · Cited by 236
Urogenital tuberculosis — epidemiology, pathogenesis and clinical features
Muneer, A., Macrae, B., Krishnamoorthy, S., & Zumla, A. I. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0228-9 · Cited by 219
Snow, K. J., Cruz, A. T., Seddon, J. A., Ferrand, R. A., Chiang, S. S., Hughes, J. A., Kampmann, B., Graham, S. M., Dodd, P. J., Houben, R. M. G. J., et al. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(19)30337-2 · Cited by 215
Self-citationSubbaraman, R., Nathavitharana, R. R., Mayer, K. H., Satyanarayana, S., Chadha, V. K., Arinaminpathy, N., & Pai, M. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002754 · Cited by 211
Pathogenicity and virulence of Mycobacterium tuberculosis
Rahlwes, K. C., Dias, B., Campos, P. C., Álvarez-Arguedas, S., & Shiloh, M. U. (2022) · Virulence · doi:10.1080/21505594.2022.2150449 · Cited by 242
Boisson‐Dupuis, S., Ramirez‐Alejo, N., Li, Z., Patin, É., Rao, G., Kerner, G., Lim, C. K., Krementsov, D. N., Hernandez, N., Ma, C. S., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aau8714 · Cited by 223
Koch, A. S., & Mizrahi, V. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.02.012 · Cited by 206
Single cell analysis of M. tuberculosis phenotype and macrophage lineages in the infected lung
Pisu, D., Huang, L., Narang, V., Theriault, M. E., Lê-Bury, G., Lee, B. T. K., Lakudzala, A. E., Mzinza, D. T., Mhango, D. V., Mitini-Nkhoma, S. C., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210615 · Cited by 199
Impact of the COVID-19 Pandemic on Tuberculosis Control: An Overview
Alene, K. A., Wangdi, K., & Clements, A. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5030123 · Cited by 202
The status of tuberculosis vaccine development
Schrager, L. K., Vekemens, J., Drager, N., Lewinsohn, D. M., & Olesen, O. F. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30625-5 · Cited by 196
Macrophage: A Cell With Many Faces and Functions in Tuberculosis
Ahmad, F., Rani, A., Alam, A., Zarin, S., Pandey, S., Singh, H., Hasnain, S. E., & Ehtesham, N. Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.747799 · Cited by 207
Is Mycobacterium tuberculosis infection life long?
Behr, M. A., Edelstein, P. H., & Ramakrishnan, L. (2019) · BMJ · doi:10.1136/bmj.l5770 · Cited by 187
Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease
Ganmaa, D., Buyanjargal, U., Zhou, X., Garmaa, G., Delgerekh, B., Enkhmaa, D., Khulan, D., Ariunzaya, S., Erdenebaatar, S., Bolortuya, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915176 · Cited by 188
Abubakar, I., Drobniewski, F. A., Southern, J., Sitch, A. J., Jackson, C., Lipman, M. C. I., Deeks, J. J., Griffiths, C., Bothamley, G. H., Lynn, W. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30355-4 · Cited by 185
Mycobacterial growth inhibition is associated with trained innate immunity
Joosten, S. A., van Meijgaarden, K. E., Arend, S. M., Prins, C., Oftung, F., Korsvold, G. E., Kik, S. V., Arts, R. J. W., van Crevel, R., Netea, M. G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97508 · Cited by 177
Summary of Notifiable Infectious Diseases and Conditions — United States, 2015
Adams, D. A., Thomas, K., Jajosky, R. A., Foster, L., Baroi, G., Sharp, P., Onweh, D. H., Schley, A. W., Anderson, W. J., & for the Nationally Notifiable Infectious Conditions Group (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6453a1 · Cited by 182
Wastewater-based surveillance as a tool for public health action: SARS-CoV-2 and beyond
Parkins, M. D., Lee, B. E., Acosta, N., Bautista, M. A., Hubert, C. R. J., Hrudey, S. E., Frankowski, K., & Pang, X. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00103-22 · Cited by 189
Coussens, A. K., Zaidi, S. M. A., Allwood, B., Dewan, P. K., Gray, G., Kohli, M., Kredo, T., Marais, B. J., Marks, G. B., Martínez, L., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00028-6 · Cited by 179
Self-citationGong, W., & Wu, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.745592 · Cited by 176
Role of Oxidative Stress in the Pathology and Management of Human Tuberculosis
Shastri, M. D., Shukla, S. D., Chong, W. C., Dua, K., Peterson, G. M., Patel, R. P., Hansbro, P. M., Eri, R. D., & O’Toole, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7695364 · Cited by 177
Knight, G. M., McQuaid, C. F., Dodd, P. J., & Houben, R. M. G. J. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30307-x · Cited by 168
Self-citationGoletti, D., Lee, M., Wang, J., Walter, N. D., & Ottenhoff, T. H. M. (2018) · Respirology · doi:10.1111/resp.13272 · Cited by 169
Safety and Side Effects of Rifampin versus Isoniazid in Children
Diallo, T., Adjobimey, M., Ruslami, R., Trajman, A., Bah-Sow, O. Y., Baah, J. O., Marks, G. B., Long, R., Elwood, K., Zielinski, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714284 · Cited by 165
Kanabalan, R. D., Lee, L. J., Lee, T. Y., Chong, P. P., Hassan, L., Ismail, R., & Chin, V. K. (2021) · Microbiological Research · doi:10.1016/j.micres.2020.126674 · Cited by 188
Metabolite changes in blood predict the onset of tuberculosis
Weiner, J. M., Maertzdorf, J., Sutherland, J. S., Duffy, F. J., Thompson, E. G., Suliman, S., McEwen, G. K., Thiel, B., Parida, S. K., Żyła, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07635-7 · Cited by 163
The knowns and unknowns of latent Mycobacterium tuberculosis infection
Boom, W. H., Schaible, U. E., & Achkar, J. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci136222 · Cited by 165
Menzies, N. A., Wolf, E. E., Connors, D., Bellerose, M., Sbarra, A. N., Cohen, T., Hill, A. N., Yaesoubi, R., Galer, K., White, P. J., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30134-8 · Cited by 150
Seedat, F., Hargreaves, S., Nellums, L. B., Ouyang, J., Brown, M., & Friedland, J. S. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30117-8 · Cited by 155
Cantini, F., Nannini, C., Niccoli, L., Petrone, L., Ippolito, G., & Goletti, D. (2017) · Mediators of Inflammation · doi:10.1155/2017/8909834 · Cited by 155
COVID-19-associated opportunistic infections: a snapshot on the current reports
Abdoli, A., Falahi, S., & Kenarkoohi, A. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00751-7 · Cited by 177
Moving tuberculosis vaccines from theory to practice
Andersen, P. L., & Scriba, T. J. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0174-z · Cited by 145
Moliva, J. I., Turner, J., & Torrelles, J. B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00407 · Cited by 159
T Cell Metabolism in Infection
Wik, J. A., & Skålhegg, B. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840610 · Cited by 158
Immunometabolic crosstalk during bacterial infection
Rosenberg, G., Riquelme, S. A., Prince, A. S., & Avraham, R. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01080-5 · Cited by 152
Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design
Ernst, J. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.06.004 · Cited by 137
Malnutrition: Modulator of Immune Responses in Tuberculosis
Padmapriyadarsini, C., Saravanan, N., Bethunaickan, R., & Tripathy, S. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01316 · Cited by 151
Seddon, J. A., Chiang, S. S., Esmail, H., & Coussens, A. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02946 · Cited by 127
The impact of the COVID-19 pandemic on the global tuberculosis epidemic
Falzon, D., Matteo Zignol, E., Bastard, M., Floyd, K., & Kasaeva, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1234785 · Cited by 126
Collins, J. A., & Osheroff, N. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00128 · Cited by 133
Kerner, G., Ramirez‐Alejo, N., Seeleuthner, Y., Yang, R., Ogishi, M., Cobat, A., Patin, É., Quintana‐Murci, L., Boisson‐Dupuis, S., Casanova, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903561116 · Cited by 130
Next-Generation Vaccines Based on Bacille Calmette–Guérin
Nieuwenhuizen, N. E., & Kaufmann, S. H. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00121 · Cited by 129
Global health 2050: the path to halving premature death by mid-century
Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01439-9 · Cited by 125
Tuberculosis prevention: current strategies and future directions
Vasiliu, A., Martinez, L., Gupta, R. K., Hamada, Y., Ness, T., Kay, A., Bonnet, M., Sester, M., Kaufmann, S. H. E., Lange, C., et al. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.10.023 · Cited by 124
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child
Ogishi, M., Yang, R., Aytekin, C., Langlais, D., Bourgey, M., Khan, T., Ali, F. A., Rahman, M., Delmonte, O. M., Chrabieh, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01388-5 · Cited by 117
QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis
Sotgiu, G., Saderi, L., Petruccioli, E., Aliberti, S., Piana, A. F., Petrone, L., & Goletti, D. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.08.018 · Cited by 114
Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Serrano, L. O. D., & Burkhart, D. J. (2017) · Journal of Nanobiotechnology · doi:10.1186/s12951-017-0319-9 · Cited by 114
Mycobacterium tuberculosis: Bacterial Fitness within the Host Macrophage
Huang, L., Nazarova, E. V., & Russell, D. G. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.bai-0001-2019 · Cited by 120
Regulatory T Cells in Mycobacterium tuberculosis Infection
Cardona, P., & Cardona, P.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02139 · Cited by 113
Tuberculosis Vaccine Development: Progress in Clinical Evaluation
Sable, S. B., Posey, J. E., & Scriba, T. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00100-19 · Cited by 120
Lymph nodes—The neglected battlefield in tuberculosis
Ganchua, S. K. C., White, A. G., Klein, E. C., & Flynn, J. L. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008632 · Cited by 127
Zellweger, J. P., Sotgiu, G., Corradi, M., & Durando, P. (2020) · La Medicina del Lavoro · doi:10.23749/mdl.v111i3.9983 · Cited by 122
Suliman, S., Luabeya, A. K. K., Geldenhuys, H. D., Tameris, M. D., Hoff, S. T., Shi, Z., Tait, D. R., Kromann, I., Rühwald, M., Rutkowski, K. T., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0366oc · Cited by 111
Scriba, T. J., Netea, M. G., & Ginsberg, A. M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101431 · Cited by 116
Evolution of virulence in the Mycobacterium tuberculosis complex
Orgeur, M., & Brosch, R. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.11.021 · Cited by 107
Petruccioli, E., Vanini, V., Chiacchio, T., Cuzzi, G., Cirillo, D. M., Palmieri, F., Ippolito, G., & Goletti, D. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.06.002 · Cited by 107
Latent tuberculosis infection: Opportunities and challenges
Chee, C. B. E., Reves, R. R., Zhang, Y., & Belknap, R. (2018) · Respirology · doi:10.1111/resp.13346 · Cited by 113
Diagnostic biomarkers for active tuberculosis: progress and challenges
Nogueira, B. M. F., Krishnan, S., Barreto‐Duarte, B., Araújo‐Pereira, M., Queiroz, A. T. L., Ellner, J. J., Salgame, P. R., Scriba, T. J., Sterling, T. R., Gupta, A., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114088 · Cited by 106
Mycobacterium tuberculosis MetabolismPreprint
Warner, D. F. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021121 · Cited by 108
Mycobacterium tuberculosis : immune response, biomarkers, and therapeutic intervention
Li, Z., Yang, L., Li, L., Ye, Z., & Gong, W. (2024) · MedComm · doi:10.1002/mco2.419 · Cited by 123
Nathan, A., Beynor, J. I., Baglaenko, Y., Suliman, S., Ishigaki, K., Asgari, S., Huang, C.-C., Luo, Y., Zhang, Z., Lopez, K., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00933-1 · Cited by 103
Krutikov, M., Faust, L., Nikolayevskyy, V., Hamada, Y., Gupta, R. K., Cirillo, D., Matteelli, A., Korobitsyn, A., Denkinger, C. M., & Rangaka, M. X. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00261-9 · Cited by 107
Laval, T., Chaumont, L., & Demangel, C. (2021) · Immunological Reviews · doi:10.1111/imr.12952 · Cited by 103
Penn‐Nicholson, A., Hraha, T. H., Thompson, E. G., Sterling, D., Mbandi, S. K., Wall, K. M., Fisher, M., Suliman, S., Shankar, S., Hanekom, W. A., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002781 · Cited by 96
Sabin, S., Herbig, A., Vågene, Å. J., Ahlström, T., Bozovic, G., Arcini, C., Kühnert, D., & Bos, K. I. (2020) · Genome Biology · doi:10.1186/s13059-020-02112-1 · Cited by 97
Ding, C., Hu, M., Guo, W., Hu, W., Li, X., Wang, S., Shangguan, Y., Zhang, Y., Yang, S., & Xu, K. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.029 · Cited by 101
The prevalence of tuberculosis infection in India: A systematic review and meta-analysis
Chauhan, A. S., Parmar, M., Dash, G. C., Solanki, H., Chauhan, S., Sharma, J., Sahoo, K. C., Mahapatra, P., Rao, R., Kumar, R., et al. (2023) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_382_23 · Cited by 96
COVID-19 and tuberculosis: the double whammy of respiratory pathogens
Shariq, M., Sheikh, J. A., Quadir, N., Sharma, N., Hasnain, S. E., & Ehtesham, N. Z. (2022) · European Respiratory Review · doi:10.1183/16000617.0264-2021 · Cited by 100
Transcriptional landscape of Mycobacterium tuberculosis infection in macrophages
Roy, S., Schmeier, S., Kaczkowski, B., Arner, E., Alam, T., Ozturk, M., Tamgue, O., Parihar, S. P., Kawaji, H., Itoh, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24509-6 · Cited by 90
Tarancón, R., Domínguez‐Andrés, J., Uranga, S., Ferreira, A. V., Groh, L. A., Domenech, M., González‐Camacho, F., Riksen, N. P., Aguiló, N., Yuste, J., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008404 · Cited by 92
Apriani, L., McAllister, S. M., SHARPLES, K. J., Alisjahbana, B., Ruslami, R., Hill, P. C., & Menzies, D. (2019) · European Respiratory Journal · doi:10.1183/13993003.01789-2018 · Cited by 93
Day, C. L., Abrahams, D. A., Bunjun, R., Stone, L., de Kock, M., Walzl, G., Wilkinson, R. J., Burgers, W. A., & Hanekom, W. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01995 · Cited by 91
Clinical Development of New TB Vaccines: Recent Advances and Next Steps
Hatherill, M., White, R. G., & Hawn, T. R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03154 · Cited by 85
Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology
Kaufmann, S. H. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00316 · Cited by 89
Diagnosis of abdominal tuberculosis: lessons learned over 30 years: pectoral assay
Abu‐Zidan, F. M., & Sheek‐Hussein, M. (2019) · World Journal of Emergency Surgery · doi:10.1186/s13017-019-0252-3 · Cited by 83
Sousa, J., Cá, B., Maceiras, A. R., Costa, A. L., Fonseca, K. L., Fernandes, A. I., Ramos, A., Carvalho, T., Barros, L., Magalhães, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15832-6 · Cited by 83
Mycobacterium tuberculosis progresses through two phases of latent infection in humans
Colangeli, R., Gupta, A., Vinhas, S. A., Venkata, U. D. C., Kim, S., Grady, C. A., Jones‐López, E. C., Soteropoulos, P., Palaci, M., Marques-Rodrigues, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18699-9 · Cited by 86
Metadata
- Authors
- Houben, R. M. G. J., & Dodd, P. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- University of Sheffield (GB)
- Corresponding author
- Houben, Rein M. G. J.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-10-25
- Volume
- 13
- Issue
- 10
- Pages
- e1002152
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC5079585
- OpenAlex
- W2533230523
- Cited by
- 2,054
- References
- 26
- Citations by year
- 2026: 160 · 2025: 259 · 2024: 242 · 2023: 243 · 2022: 208 · 2021: 237 · 2020: 257 · 2019: 205 · 2018: 167 · 2017: 67 · 2016: 5
- FWCI
- 22.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Bill and Melinda Gates Foundation (US) (OPP1084276)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- latent tuberculosis infection, global burden of disease, annual risk of infection, isoniazid-resistant tuberculosis, recent infection, End TB Strategy, Gaussian process regression, WHO regions, tuberculosis control, uncertainty quantification, demography
- MeSH terms
- Antitubercular Agents, Humans, Isoniazid, Mycobacterium tuberculosis, Risk, Global Health, Incidence, Prevalence, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
